Please wait
HEALTHCARE · Pharmaceutical Preparations · Price, fundamentals, signals, and forward-looking context in one research view.
HEALTHCARE
₦397M
N/A
N/A
Current price
₦1.83
Updated Updated 10h ago
Open
N/A
Previous close
₦1.83
Day range
N/A
Volume
N/A
Limited data
Awaiting filing
No current yield
65/100 measured
Moderate liquidity
The latest saved price history for PHARMDEKO, with its range and direction at a glance.
Eye captured this official filing and document processing is still underway.
Pharma Deko Plc engages in manufacturing, packaging, and marketing pharmaceutical and consumer products in Nigeria. It operates through three segments: Pharma, Consumer, and Contract. The company offers cough and vitamins products under the Parkalin Pediatrics, Parkalin Chesty, and Parkalin with Codeine brands, as well as drops and syrups under the Vitacee and Pharmadec brands; Revitone blood tonic, Salins Liniment and Antasil tablets, Amoquin tablets, and Garlic tablets; prescription drugs, including Omepraz Capsules, Sparxin, Pidiclox dry powder and capsules, Amycin dry powder and capsules, Hexedene, and Parkaprim suspension and tablets; and carbonated soft drink (CSD). It also engages in contract manufacturing and packaging of both pharmaceutical and fast-moving consumer goods. The company was formerly known as Parke-Davis & Co. (Nig.) Limited and changed its name to Pharma Deko Plc in 1980. Pharma Deko Plc was founded in 1962 and is based in Agbara, Nigeria.
Investors usually follow PHARMDEKO for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
This official filing has been discovered and is awaiting full extraction or review.
This official filing has been discovered and is awaiting full extraction or review.
Position: Director. Reported on 7 Nov 2022. From an official NGX Directors Dealings filing. Director dealing source fetched but no extractable text was found.
This official filing has been discovered and is awaiting full extraction or review.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
This official filing has been discovered and is awaiting full extraction or review.
This official filing has been discovered and is awaiting full extraction or review.
This official filing has been discovered and is awaiting full extraction or review.
Director dealings
1
Reported buys, sells, and mixed dealings.
Official filings
10
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
40
Captured updates we can trace.
Whisone is bearish because the bullish case is not yet strong enough to lead while fundamentals are weak at 15/100. Whisone has low conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Sentiment
Market mood from flow, events, and attention.
ROE
-25.5%
Return on equity
ROA
-7.8%
Return on assets
Debt / equity
0.03
Lower is usually safer.
P/B ratio
0.39
Useful for book value support.
74/100
Direction
Cautious
Main supports
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Liquidity looks thin, so even a good thesis may take longer to show up in price.
Fair value
₦1.82
Analyst view
n/a
Forecast refresh
Updated 10h ago
Quality score
28
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
41.1
Momentum is currently in a neutral range.
Recent trend
Sideways
+0.0% across the latest saved price window.
Volatility
Low
Beta is -0.12. Price has historically moved more calmly than the wider market.
52-week position
N/A
A complete 52-week range is not available.
Volume confirmation
N/A
Comparable volume data is not available.
PHARMDEKO may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
PHARMDEKO may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
PHARMDEKO may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
PHARMDEKO may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
PHARMDEKO may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
PHARMDEKO may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
PHARMDEKO may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
PHARMDEKO
Pharma-Deko Plc
Price: ₦1.83
P/E: n/a
Yield: N/A
EKOCORP
Eko Corporation Plc
Price: ₦5.80
P/E: N/A
Yield: N/A
FIDSON
Fidson Healthcare Plc
Price: ₦93.55
P/E: 22.27
Yield: 1.6%
MAYBAKER
May & Baker Nigeria Plc
Price: ₦40.00
P/E: 12.66
Yield: 1.0%
Industry
Pharmaceutical Preparations
Founded
1962
Employees
50
Exchange
NGX
Ticker
PHARMDEKO
